NAPSRxx Exam Answers
Question
1. How are drugs sorted into therapeutic groups and classes?
A. first by the conditions that they are used to treat. and then by their mechanisms of action
B. first by their mechanisms of action. and then by their therapeutic effects
C. first by their side effects. and then by their therapeutic effects
D. first by their toxicity. and then by their effectiveness
2. Bone marrow transplants...
A. require that the patient first undergo chemotherapy or radiation to kill the diseased stem cells and promote white blood cell production.
B. are a type of stem cell therapy. unless patient's own cells are reinjected.
C. are always a type of stem cell therapy.
D. can help people with leukemia. a condition in which the body does not produce enough white blood cells.
3. What does AMA stand for?
A. American Medical Academy
B. American Medical Accreditation
C. American Medical Association
D. Association of Medical Assistants
4. What section of a drug's package insert describes situations in which the drug should not be used because the risks outweigh the therapeutic benefits?
A. adverse reactions
B. contraindications
C. overdosage
D. warning/precautions
5 What is tertiary care?
A. adding medications together to achieve a better clinical effect
B.highly specialized medical and surgical care provided by a large medical center for unusual or complex medical problems
C. receiving medical or surgical care that does not require an overnight stay in the treatment facility
D. seeing a physician for routine checkups and general healthcare
6. Which of the following is NOT one of the stages in the classic approach to brand development strategy covered in your manual?
A. brand personality
B. brand positoning
C.brand quality
D. brand values
7 What are vasodilators used to do?
A. decrease vascular resistance and increase blood flow
B. mimic pathogens to stimulate the immune system
C. narrow the blood vessels
D.stimulate the CNS to make the heart beat faster
8. What is the name of the condition that occurs after a specific dose of a drug is given at such regular intervals that absorption and elimination (and therefore drug plasma concentration) have become fairly constant?
A. homeostasis
B.steady state
C. titration
D. tolerance
9. Which statement is TRUE about ocular administration?
A. Ocular administration is primarily for drugs that must cross the blood-brain barrier.
B. Ocular administration is used primarily to treat the eye.
C. Ocular administration is used when a drug must enter the bloodstream immediately.
D. Ocular administration is used when a drug must produce immediate effects on the brain or spinal cord.
10. Which entities invest's the most money in pharmaceutical R&D?
A. Canadian pharmaceutical companies
B. the NIH
C. the U.S. Government
D.U.S. pharmaceutical companies
11. How are most drugs excreted?
A. via the bloodstream
B. via the heart
C. via the kidneys
D. via the skin
12. Over the last few decades, what has happened to legal limitations on sales' reps discussions about off label uses?
A. Limitations have decreased.
B. Limitations have increased significantly.
C. Limitations have increased slightly.
D. Limitations have remained about the same.
13. Answer:Branding name
14. What does it mean if two drugs are at parity?
A. Both drugs are essentially in a neutral position.
B. Both drugs are generics.
C. Both drugs have exclusive preferred status.
D. The two drugs are bioequivalent.
15 Who is most likely to benefit from electronic sampling programs?
A. Everyone would benefit equally from electronic sampling programs
B. physicians in hospitals who are too busy to see representatives
C. physicians in rural areas who are not as frequently visited by representatives
D. physicians in urban areas who are too busy to see representatives
16. When referring to medication dosage, which abbreviation means "one-half':
A.MS
B.OH
C. SM
D. SS
17 What is an internist?
A. a physician who practices internal medicine
B. a physician's intern
C. a type of oncologist who specializes in chemotherapy
D. an internal sales representative
18. Which of the following is a type of white blood cell?
A. erythrocytes
B. insulin
C. Lymphocytes
D.HCs
19. Why are novice sales representatives often placed in charge of negotiating MCO formularies?
A. to become more familiar with the healthcare industry
B. to become more familiar with their territories
C. P&T committees are more receptive to new faces.
D. They are not. This job is usually reserved for more experienced reps.
20. What distinguishes pharmacodynamics from pharmacokinetics?
A. Pharmacodynamics studies a drug's ex vivo effects.
B. Pharmacodynamics studies how drugs affect the body.
C. Pharmacodynamics studies the how the body affects drugs.
D. Pharmacodynamics studies the time required for a drug's absorption.
21 What proportion of the drugs tested on human subjects are eventually approved by the FDA?
A. about 20%
B. about 60%
C. about 70%
D. about 95%
22. According to a study discussed in your manual, how do most physicians prefer to receive their drug samples?
A. by borrowing them from hospitals
B. by ordering them over the Internet
C. by trading them for services
D.directly from sales representatives
23. Which of the following is an example of a central value?
A. I buy Advil to show that I'm a modern consumer.
B. I like Advil because we were both born in the 80s.
C. I prefer Advil because I like the flavor.
D. I prefer Advil because it's easier to swallow.
24. Which of the following specialties likely has the MOST emergency calls?
A. cardiology
B. psychiatry
C. urology
D. All specialists have the same number of emergency calls.
25. What affects the rate of active transport?
A. the availability of carriers. but not energy
B. the availability of energy. but not carriers
C. the availability of carriers and energy
D. neither the availability of carriers nor the availability of energy
26. Over the last few decades, what has happened to the FDA approval time for new drugs?
A. It has been lengthened to ensure safer drug products.
B. It has been lengthened to limit DTC marketing
C. It has been shortened to improve drug quality
D. It has been shortened to reduce the cost of new drug development.
27. Which of the following would NOT help improve compliance?
A. patients liking their providers
B. patients using only one pharmacist
C. pharmacists understanding how generics differ from brand name drugs
D. support groups
28. Which entity chooses a drug's trade name?
A. the drug's inventor
B. the drug's manufacturer
C.the FDA
D. the United States Pharmaceutical Council
29. What type of stem cells are obtained from embryos and can develop into any cell type?
A. multipotent
B. pluripotent
C. totipotent
D. All XXXX cells XXX develop XXXX XXX cell XXXX.
30. As the XXXXX a XXXXXXX XXXX for a prescription increases, XXXX XXXXXXX to the likelihood that the XXXXXXX XXXX fill it?
X. XX XXXXXXXXX.
B. It increases.
C. XX XXXXXXX unaffected because XXX XXXXXXXXXXXX is XXXXXX.
D. It XXXXXXX unaffected because XXX XXXXXXXXXXXX's XXXXXXXXX cost is XXXXXX by its XXXXXXXXX XXXXX.
31. XXXX XXXXXXXXXXX movements come from XXXXX type XX XXXXXX tissue?
A. XXXXXXX and smooth
B. only XXXXXXXX
C. XXXXXXXX XXX XXXXXXX
D. skeletal and smooth
XX. XXXXX XX XXX following XX NOT XXX of the body's major organ systems?
X. the cardiovascular system
X. the cellular system
X. the gastrointestinal XXXXXX
X. the XXXXXXXXXXXXXXX XXXXXX
33. How do XXXX XXXXX exert their primary physiological effects?
A. XX activating synapses XXXXXXX different types XX tissues
X. XX XXXXXXX to cell receptors XXXX are sensitive to their presence
C. XX inhibiting XXXXXXXX XXXXXXX different types XX XXXXXXX
X. through XXXXXXX mutation
XX. XXXX is the most XXXXXXXX XXXXXX of XXXXXXXXXXX for determining therapeutically equivalent drug products?
A. AMA XXXXX
X. XXXX XXXX
C. FDA XXXX XXXX
D. XXXXXX Book
35. What XXXX XXXXXXXXXXXX XXXX?
A. beneath the XXXXXXXXXXXX
X. XXXXXXX the muscle tissue
X. beneath the outer skin
D. beneath XXX suture
XX. XXXX XXXXXX a XXXXX XXXXXXXXXXXXXX do if XXX XX XXX XXXXX XXXXXX in a drug XXXXXXX XXX XXXXXXXXX?
X. XXX staff XXX permission to move XXXX XX the other products in XXX XXXXXXX
X. XXX staff XXX permission XX XXXXX away XXXXXXX XXXXXXXX in XXX XXXXXXX
C. XXX the doctor XX he still needs XXXX XX the XXXXX products in XXX cabinet
X. XXXXXXXXXXXXXXX XXXX XXXX largest XXXXXXXXXXX' XXXXXXXX out XX XXX XXX
XX. It is inappropriate XXX XXXXXXXXXX' XXXXXXXXXXX behaviors XX be XXXXXXXX by XXXXX personal tastes and XXXXXXXXXXXXXX
A. XXXX
X. XXXXX
38.The XXX defines XXX as the active__ ingredient in a XXXX, XXXXX produces XXX desired XXXXXX in the body.
X. XXXXXXXXXXXXXX
X. XXXXXXXX
X. potent
X. primary
XX. What XXX the 2 XXXXX classifications XX XXXXXXXXXXX?
A. distributors and supply chains
B. pharmacists and NAMs
C. primary and secondary wholesale distributors
D. retailers and institutions
40.What XXXX describes the usage XX a medication XXX purposes other XXXX XXX FDA-approved XXXXXXXXXXX XX XXX XXXXXXXX?
A. contraindicative indication
B. XXX-XXXXXXXXXX XXXXX
C or D. off-XXXXX
41. XXXX XX XXX XXXXXXX XXX XXXXXXXXXXXXXXXX?
A. XX
B. PC
X.PK
D. pT
42. The XXXXXX XXXXX of a XXXX XXXX XX XXXX XXXX XXX XXXXXXXXXX XX XXXXX as XXX XXXXXXXXXXX XXXXXX.
A. XXXX
X. FALSE
XX. XXXX XX XXXXXXXXX XXX a characteristic of a pharmaceutical XXXXX XXX?
X. XXXXXXXXXXXXXX XXXXX XXXX XXX XXXXXXXXX XXX XXXX.
B. Pharmaceutical XXXXX XXXX XXX XXXXXXXX.
X. Pharmaceutical sales XXXX are XXXXXXX.
D. Pharmaceutical sales reps are XXX XXXXXXXXX about XXXXXXXXXXX.
44. What XXXXXX grants drug XXXXXXX?
X. XXX XXX
B. XXX FDA XX the XXXX is over-the-counter XXX XXX U.S. XXXXXX XXX Trademark Office XX XXX XXXX is XXXXXXXXXXXX
C. XXX FDA XX XXX drug is XXXXXXXXXXXX and the U.S. Patent and Trademark Office XX the drug XX over-the-XXXXXXX
X. XXX X.S. Patent XXX Trademark XXXXXX
45. XXXXX of the XXXXXXXXX XXXXXX to all active XXX inert pharmaceutical ingredients in a XXXX, XXXXXXXXX fillers XXX XXXXXX?
A. formulation
B. XXXXXXXXXX
X. peptide
D. saccharide
XX. What is the XXXXXXXXXX XXXXXXX XXXXXXX XXX efficacy?
X. Doctors XXXXXX XXXX potent XXXXX.
B. XXXX manufacturers XXXXXX more potent drugs.
C. Potency XXXXXX XX the XXXX's effectiveness. while efficacy refers XX XXX XXXXXXXX.
X. XXXXXXX refers to the XXXX's strength, while XXXXXXXX XXXXXX to XXX effectiveness.
XX. What XX XXX XXXXXXX XXXXX XX XXXXXXXXX XXXXXXXX XXX a XXXXX XXXXXXXXXXXX?
A. a XXXXXXXXXXXXX program
X. an XXXXXXXXX's XXXXXX
C. a bachelor's XXXXXX
X. a XXXXXXXX XXXXXX
48. XXX XXXX names XXXX a XXXX have?
X. XX XXXX XXXXX
X. at XXXXX XXXXX
X. XX XXXX five
D. XX XXXXX XXXX
49. How has a longer development XXXX increased XXX XXXX of XXXXXXXX a XXX XXXX to XXXXXX?
XXXXXX: Increasing the XXXX of capital
XXXXXXXXXXXX (XXXXXX Not XXXXX so XXXX out in below para): XXXXXXXXXXX XXXXXXXXXXX XXXX XXXXXXXXXXXX increase the XXXX of XXXXXXXX a new drug XX XXXXXX by increasing XXX cost XX capital XXXXXX for R&XXX;X. The cost XX capital XXXXXXXXX XX XXXXXXXXX are exposed to Economic Risk XXX uncertainty XXXX a longer XXXXXX XX development time. XXXXXXXXX FDA XXXXXXXXX XXX XXXX approval times XXXX XXXXXXX XXXXXXXXX the cost of developing new drugs.
50. Senior citizens consume over times as many pharmaceuticals as people XXXXX 65.
A. three
B. five
X. ten
X. XXXXXXX
51. XXXX agency XXXXXXXXX the XXXXXXXXXXXX XXX use XX XXXXXXXXX?
X. DEA
X. FTC
X. OIG
X.TSA
52. What is XXXXXXX XXXXXXXXX?
A. a type XX pinocytosis
X. XXXXXXXX XXXXXXXXX via vesicles
X. the XXX of energy XX XXXX a XXXXXXXXX XXXX XXXX a low concentration XXXXXXXX XX a XXXX XXX
D. when a substance XXXXXX moves XXXXXXX a XXXXXXXX XXXX a XXXX concentration gradient to a XXX XXX
53. XXXX XXX XXX MAIN XXXXXXXXXX XX XXXXX under XXX XXXXXXXXXXXX?
X. active XXXXX XXX XXXXXX placebos
B. XXXXXXXXXXXXXXXXXX XXX XXXXXXXXXXXXXX
X. non-XXXXXXXXXXXX and nutraceuticals
X. XXXXXXXXXXXX XXX non XXXXXXXXXXXX
XX. XXXXXX: XXXXXXXX
XX. XXXX are XXX metabolites?
A. active XXXXXXXXXX
X. XXXXXXXX XXXXXXXXXX
C. XXXXXXXXXX
X. products of metabolism
XX. When a drug is administered orally, where XXXX XXXXX-pass XXXXXXXXXX XXXXX?
X. intestine
X. XXXXX
X. XXXXXXXX
D. stomach
XX. XXXX is the XXXXXXX term XXX XXXXXXXX?
A. assay
B. XXXXX
C. instillation
D. XXXXXXXX
58. XXXXX XX the XXXXXXXXX is NOT XXXX XX XXX XXXXX Step Cascade XX XXXXXXX?
A. XX a consultant. not a rep
B. identify XXXX your product does
C. XXXXXXX
X. XXXXXXXXX the power of XX
XX. XXXXX part XX a XXXXXXXX XXXXXXXX XXXXX is frequently referred XX XX XXX XXXX map?
X. abstract
B. XXXXXXXX
X. letter to XXX editor
X . methods
XX. XXXXX XX XXX following is a XXXX XXXXXX ingredient in lung surfactants?
A. animal XXXX XXXXXXX
X. XXXXXXXXXX
X. sympathomimetic drugs
D. XXXXXXXXXXXX
XX. What XXXX XXXXXXXXXX XXXX?
A. child XXXXXXXXXXXXX
X. injection
X. XXXX
D. XXXXXX
62. XXXXX term XXXXXXX a XXXX of XXXXXXXXX XXXX XXXXXXXX XXX action XX a drug or XXXXXXX?
X. adjuvant
B. XXXXXXXXX
C. XXXXXX
D peptide
63. XX a sales representative's XXXXXXX XX XXXXXX XX the second tier of a XXXXXXXX three-XXXX XXXXXXXXX, XXXXX XX the following is most likely true?
A. XX XXX XXX XXXX reviewed by the X&X XXXXXXXXX.
X. XX XX in a XXXXXXX XXXXXXXX unless it is at XXXXXX XXXX other XXXXX.
C. XX probably XXX exclusive preferred XXXXXX if it is not XX XXXXXX with any other drugs.
D. It will essentially XXXX itself if it XX XXXXXXX XXXXXXXXX XXXXXXXXX XXXXXX.
XX. Which of the XXXXXXXXX is NOT one XX the four basic transport mechanisms?
X. XXXXXX XXXXXXXXX
X. XXXXXXXXXXX
X. passive XXXXXXXXX
X. pinocytosis
65. Which statement accurately XXXXXXXXX a XXXXXXXXXXXX between drug agonists XXX antagonists?
A. Agonists and antagonists can be XXXX together.
B. Agonists and XXXXXXXXXXX should not XX used together.
C. XXXXXXXXXX drugs activate receptors. XXXXX agonists block access to receptors.
D. Antagonists are XXXXXXXXXX whereas XXXXXXXX are man-XXXX.
66. What XX XXX XXXXX of XXX effects and movement XX drugs in XXX XXXXX body?
X. anatomy
B. XXXXXXXX
C. clinical XXXXXXXXXXXX
X. XXXXXXXXX
XX. According XX XXXX manual, XXXX XX a common XXXXXXXXX that physicians XXXX about XXXXXXXXXXX XXXXXXXX methods?
X. that drug XXXXXX supply XX too XXXXXXXXXXXXX
X. XXXX patients XXX less XXXXXX XX take free samples because they XXXXX XXXX XXX lower quality
X. XXXX XXXXXXXX do not XXXX seeing XXXX XXXXXXXXXXXXXXX in XXXXX offices
X. that they receive XXX many XXXX XXXXXXX
68. XXXXX XX XXXXX entities is formed by two or more XXXXXXXXX or XXXXX healthcare XXXXXXXX to XXXXXXXXX reduced rates with its aggregated purchasing power?
X. GPO
B. XX-state wholesaler
X. XXX
D. RPO
69. XXXX is another XXXX XXX a drug XXXXXXX from a XXXXXXXX compound?
A. XXXXX XXXXXXXX
X. oligonucleotide
X. XXXXXXXXX
X. XXXXX XXXXXXXX
70. XXXX is the XXXX common policy XXXXXXXXX pharmaceutical reps XXXXXXXXXX XXXX XXXXXXX in XXXXXXXXX?
X. XX XXXXXXX XXX. drug sampling is XXXXXXXXX in all XXXXXXXXX.
X. XX federal XXX. it XX up XX individual XXXXXXXXXX. not the XXXXXXXX.
X. XXXX sampling is XXXXXXXXXX. but not XXXXXXXX.
X. XXXX sampling XX XXXXX XXXXXXXXX.
71 XXXXX XX the XXXXXXXXX would XXXX you XXXXX XXXXX with a XXXXXXXXX?
X. asking XX he or XXX is having XXX problems XXXX the managed care XXXXXXXX of your products
B. repeating a XXXXXXXX you already asked
X. XXXXXXXXXX XXX XXXXXX XXXXX with a XXX poster in the break XXXX
X. XXXX of XXXXX would help you build XXXXX with a XXXXXXXXX.
72. What XXXX denotes XXX difference between the usual XXXXXXXXX XXXX and the dose that XXXXXXX XXXXXX or XXXX-XXXXXXXXXXX side effects?
X. dose-response XXXXXXXXXXXX
X. XXXXXX of safety
X. XXX XXXXXXX effect
D. XXXXXXXXXXX window
73. XXXX are XXXXXXXXXX?
A. a type XX cell XXXXXXXX XX which antagonists XXXX XX XXXXXXXX XXX XXXXXXX XX XXX body's natural XXXXXXXX
B. XXXXXXX term for generic equivalents
X. XXXXX of XXXXXX besides XXX XXXXXX sites XX action
X. XXX inert ingredients in a drug formulation
XX. XXXX XX another XXXX for XXX AWP?
X. XXXX-XX-XXXX price
X. XXXXX price
X. list XXXXX
D. XXX-XXXXX price
XX. XXXXX of these is XXX most likely use XXX a XXXXXXXXXX agent?
X. XX induce XXXXX
X. to XXXX XXX urine XXXX alkaline
C. to supplement oral XXXX XXXXXX
D. XX treat hyperthyroidism
XX. As of November XXXX, XXXXX of XXXXX XXXXXXXXX XXX XXXXXXXXX XXX advertising XX prescription XXXXX?
A. Canada
B. Japan
C. Spain
D. none of these
77. Why are XXXX drugs XXXXX taken on an empty stomach?
X. XX XX more wholly XXXXXXXX XX the stomach
X. to XXXXXXXX XXXXXXXXXX XX XXX intestine
X. XX minimize nausea
X.XX pass through XXX stomach more quickly
78. What is XXX factor XXXX differentiates community XXXXXX XXXXXXX XXXX hospitals?
A. Community XXXXXX XXXXXX formularies are XXXX XXXXXXXXXXX.
B. Community XXXXXX centers have XXXXXX XXXXXXXXXXXXX XXXXX.
X. Newer brand name drugs XXX easier XX XXXXXX XX XXXXXXXXX health centers.
X. XXXX of these
79. XXX does drug XXXXXXXX provide a social benefit?
X. XXXXXXX donate XXXXX unused XXXX samples XX XXXXXXXXX.
X. XXXXXXX XXXXX XXX XXXX XXXXXXX to XXXXX patients XXX otherwise XXXXX not afford it.
C. XX XXXXXX patients XX XXX out different XXXXXXXXXXXX medications XXXXXX consulting XXXX physicians.
D. Drug XXXXXXXX provides a XXXXXX benefit in all of these ways.
XX. Which XXXXXXX term denotes XXX XXX of a XXXXXXXXXXX to XXXXXX to XXX XXXXX?
A. XXXXXXXXXXXX
B. cardioversion
X. catheterization
D. XXXXXXXXXXXXXXXX
XX. What XX XXXXXXX coatings do?
X. XXXXXXXXXX vomiting
X. help XXXXX dissolve in the stomach
C. help drugs XXXXX the bloodstream XXXX XXXXXXX
D. prevent dissolution in XXX XXXXXXX
XX. What XX XXX XXXXXXXX of exclusivity XXX orphan drugs?
A. 6 months
X. X year
C. 7 XXXXX
X. 15 XXXXX
XX. XXXX do XXXXXXXX Account Managers do?
A. XXX as the XXXXX reps' XXXXXXX XXXXX of XXXXXXX with the rest of the corporation
B. XXXXXX XXX XXX approval XXXXXXX
C. negotiate XXXXXXXXX with XXXX and PBMs
D. XXXX only XX XXXXXXXXXX
XX. What does it XXXXXXX mean XX a XXXX XXXXXX XX XXXXXXXXX?
A. XXXXXXXXXX XXX choose whether XX return XXX XXXX or dispense it.
X. XXX FDA has XXXXXXXXXX XXXX the drug XX XXXXXXXXX safe. XXX ineffective.
X. The manufacturer has XXXXXXXX the product XX its own. but XXXXXXXXXX XXXX the XXX XXXXXXXXXX.
X. XXX manufacturer XXX XXXXXXXX XXX XXXXXXX XXXXXXX XXXXXXXXXXX with the FDA.
XX. XXXXX XXXXX XX XXXXXXXX XXXXXX is also known XX XXX pivotal XXXXX?
X. Phase I
X. Phase III
X XXXXX IV
X. Phase IX
XX. XXXXXX XXXXX phase of clinical XXXXXX XX the new drug's XXXXXX and effectiveness XXXXX XXXXXX in XXX XXXXXX XXXXX?
X. preclinical
B. Phase I
C. Phase XX
X. XXXXX III
XX. XXX do antacids work?
X. XX XXXXXXXXXX blood XXXX to the XXXXXXX
B. XX lowering gastric XX
X. XX XXXXXXX gastric XX
D. by XXXXXXXXXXX XXXXXXXXXXX formation by XXX liver
XX. XXXX XX XXX of XXX biggest time XXXXXXX XXX a pharmaceutical XXXXX XXX?
X. Caterers
B. XXXXXXXXX
C. receptionists
D. travel time
89. What happens XXXX XXXXXXXXXXX XX XXXXXXX?
X. XXXXX XXXXXXX XX XXXXXXXXX cross XXX XXXXXXXX in XXXX directions
B. molecules stop moving
C. XXX concentration gradient XXXXXXXXX indefinitely
X. XXX XXXXXXXXXXXXX gradient XXXXXXXXX indefinitely
90. XXXX XXX XXX most XXXXXX XXXXXXX used in XXXX XXXXXXX?
A. autologous XXXXXXXX
B. XXXXXXXXX
C. naked DNA
X. viruses
91. XXXX is the percentage XXX XXXX the XXXXXXXXX XXXX the wholesaler XXX XXXXXXXXXXXX?
X. margin fee
X. XXXXXXXX
C. XXXXXXXX XXX
X. XXXXXXXX
92. XXXX XX the difference XXXXXXX a XXXXXXX (or XXXXXXXXXX) XXXXXXXX, and a XXXXXXX reaction?
A. Chronic reactions XXX exaggerated. XXXXXXX delayed reactions XXX idiosyncratic.
X. XXXXXXX reactions occur XXXX XXXXXX treatment. whereas delayed reactions XXXX occur XXXXXX withdrawal.
C. XXXXXXX XXXXXXXXX XXXXXXX for a long XXXX. whereas delayed XXXXXXXXX take XXXX time XX develop.
D. Delayed reactions are XXXXXX idiosyncratic. but XXXXXXX reactions XXX not.
XX XXXX is XXXXXXXX XXXXXX?
A. federally funded research XXXXXXXXX
B. XXX effect XX XXXXXXX dosage
C. the response produced by a XXXXXXXXXX
X. XXX XXX of treatment XXXXX in XXXXXXXXXXXX
94. Which XX the XXXXXXXXX is an example XX noncompliance?
X. a XXXXXXX XXXXXXXXXX to take a XXXX at a XXXXXXXXX time XX day
B. a patient XXXXXX a drug. XXX XXXX XXXXXXX it has XXXX XXXXX-mandated
X. a pharmacist dispensing a generic equivalent of a drug instead XX XXX brand name
X. a XXXXXXXXX XXXXXXXX XX prescribe a XXXX because he or XXX does XXX trust XXX clinical XXXXXXX XX it
XX. What is XXX XXXXXXX circulation time of blood?
X. XXXXX a minute
X. about 5 XXXXXXX
X. about X XX XX minutes depending XX the XXXXXXX's age XXX XXXXXX XXXXXXXXXX
D. about XX XXXXXXX
96. XXXX is XXX XXX in XXXXX pharmaceutical selling is XXXXXXXXX XXXX XXXXXXX in XXXX XXXXX industries?
X. In XXXXXXXXXXXXXX sales. the XXXXXXXXX-makers. XXXXXXXXX. XXX XXXXXX XXX usually XXX same XXXXXX.
X. Pharmaceutical selling takes XXXX XXXX because XXXXXXX are so busy.
C. XXXXXXXXXXXXXXX XX XXX sell XX the XXX user XX XXX XXXXXXX.
D. Representatives XX sell to XXX end XXXX XX the XXXXXXX.
XX. XXXX XXXX types of entities do primary XXXXXXXXX distributors XXX most XX their XXXXX?
A. XXXXXXXXXX
X. buying clubs
C. manufacturers
X. XXXXXXXXXX
98.XXXX is the Office XX XXX XXXXXXXXX XXXXXXX (01G)?
A. a department in pharmaceutical XXXXXXXXX
B. an XXX of XXX XXXXXXXXXX of Health and XXXXX Services
X. an XXX XX the European XXXXXXXXX Agency X an arm XX the XXX
XX. XXXX XXX XXXXXXX XXXXXXXX to XXXXXXXX when deciding XXXXXXX or not XX prescribe a particular XXXX?
X. XXXXXXXX XX XXXX over XXXXXXX of XXXX
X. XXXX no XXXXX with adverse effects XXXXXX XXXX be XXXX
C. XXX XXXXXXXXXXX XX OTC drugs
D. XXX severity of XXX XXXXXXXX being XXXXXXX and XXX effect it XXX on the patient's XXXXXXX of XXXX
100. Which XXXXXX assigns a XXX drug XXX generic XXXXX?
A. the XXXX's XXXXXXXX
B. the XXXX XXX XXXX XXXXXXXXXXXXXX
X. the United XXXXXX Adopted XXXX Council
D. XXX United XXXXXX Pharmaceutical Council
XXX. XXXXX can be XXXX days XXXXXX their expiration XXXX.
A. X-7 days. XXXXXXXXX XX XXX most current monograph.
B. X-XX XXXX. XXXXXXXXX XX state laws
X. X-90 days. XXXXXXXXX XX the type of XXXX and its XXXXXXXXXXX class.
D. none XX these
XXX. XXXX is XXXXXXXXX for a drug XX be XXXXXXXX XXXXXXXXXXX XXX the XXXXXXX?
A. XXX XXXX must be XXXXX-soluble. and not XXXX XXX tightly to proteins in XXX bloodstream.
B. XXX drug XXXX have a XXXXXXXXXXXX bilayer and XX XXX-XXXXX-soluble.
C. The drug XXXX have a XXXXXXXXXXXX XXXXXXX XXX bind XXXX to proteins in XXX bloodstream.
X. XXX drug must XXX XX water-soluble.
103. Which XXXXXXXXXXXX or XXXXXXXXXX initiates the clinical XXXXX and XXXXXXXX the XXXXX?
A. clinical XXXXXXXX XXXXXXXXXXXX
B. XXXXXXXXXXXX
X. XXXXXXXXXX
X. sponsor
104. The name XXXXXXXXX the XXXXXX or XXXXXXXXX structure of a drug.
A. chemical
B. generic
X. XXXXXXXXXXXXXX
X. proprietary
105. XXXXX XXXXX XXXX, XX it acceptable or XXXXXXXXXXXX XXX a XXXXXXXXXXXXXX sales rep to take a XXXXXXXXX and XXX XXXXXXXXX's spouse to a fundraising XXXXXX?
A. XXXXXXXXXX if only XXX XXXXXXXXX XXXXXXX
X. XXXXXXXXXX XX only XXX physician attends. XXX XXX total is XXXXX $XXX
C. acceptable XX the XXXXX XX under $100
D. XXXXXXXXXXXX
106. The Hatch-XXXXXX XXX XX XXXXXXXXXX the XXXX significant XXXX-related XXXXXXXXX XXX pharmaceutical industry XXXXX XXXX.
X. XXXXXXXXXX
X. legislation
C. XXXXXXX
D. XXXXXXXX
XXX. What term XXXXXXX the XXX XXXXXX, XXXXXXX, or degree to which a substance XX XXXXXXXXX or harmful to the body?
X. caliber
X. chronicity
X. indication
D. toxicity
108. What XXXXX has MOST XXXXXXXXXX XXXXXXXXX' desire XX XXX XXXX OTC XXXXXXXXXXX?
X. a weaker patients' rights XXXXXXXX
B.lack of insurance coverage
C. XXXX XXXXXXXX on the Internet
X. proliferation of XXXXXX remedies
109. XXXX is the degree to which a medication produces a therapeutic effect?
X. XXXXXXXXX
X. efficacy
X. XXXXXXXX
D. vector
XXX. What is the most important XXXXXXX XX electronic prescribing?
X. XXXXXX
B. XXXX
C. XXXXXXXXX
X. XXXXXX
XXX. XXXX does the FDA XXXXXXXX XXXXXXX XXXXX?
A. only if they XXX XXXXXXX generics
B. only if they XXXX been contested
X. XXXXXX
X never
112. Which phase of XXXXXX largely XXXXXXXXXX the clinical XXXX?
A. preclinical trials
B. Phase II trials
C. XXXXX XXX XXXXXX
X. Phase IV trials
XXX. What XX an advantage of XXXXXXXXXXX vaccines over XXXXXXXXXX XXXXXXXX?
A. Inactivated XXXXXXXX XXX less expensive to XXXXXXX.
B. XXXXXXXXXXX vaccines XXXX a higher probability of eliciting the XXXXXXX immunological XXXXXXXX.
C. XXXXXXXXXXX vaccines have a more stable XXXXX XXXX.
X. XXXXXXXXXXX vaccines XXXX require a XXXXXX XXXX.
114. Which medical XXXX XXXXXXX a XXX XXXXXX XX XXXXXX due to XXX XXXXX flow?
A. potentiation
X. ischemia
X. TID
X. XXXXXXXXX
115. XXXX XXX XXX two main XXXXX of prescription drug marketing?
X. (1) marketing XX insurance XXXXXXXXX. and (X) XXXXXXXXX to pharmacies
X. (X) PBM marketing. XXX (2) XXXXXXXXX to XXXXXXXXXXX
X. (X) professional XXXXXXXXX promotions. XXX (X) XXXXXX-to-XXXXXXXX advertising
D. (1) XXXXXXXX-funded XXXXXXXXX. and (X) physician-funded XXXXXXXXX
116. What is XXX site of XXXXXXXX XXX XXXXXXXXXXXX injections?
A. fatty tissuebeneath XXX surface XX the XXXX
X. XXXXXXXXX tissue
X. XXXXXX XXXXXX
X. XXX stomach, via a special XXXX XX XXXXXX
117. XXXX must be XXXXXXXXX in the Description XXXXXXX XX a pharmaceutical XXXXXXX insert?
X. XXXXXXX XXXXXXX
B. XXXXXXXXX XX action
C. pharmacokinetics
X. XXX proprietary name XXX the XXXXXXXXXXX XXXX
118. XXXX is the XXXXX of a XXXXXXXXXX's XXXXXXX as it XXXXXXX through XXX body?
X. XXXXXXXXXXXXXXXX
B. XXXXXXXXXXXXXXXX
X. pharmacogenomics
X. XXXXXXXXXXXXXXXX
119. XXXXXXXXX XXXXXXXX XXXXXXXX from XXXXXX they like, trust, XXX XXXXXXX. XXXX XX called the
X. XXXXXXX of XXX XXXX
X. first time XXXXXXXXX
X. likeability factor
D. XXXXX of knowledge
120. What XX penicillin's XXXXXXX mechanism XX XXXXXX?
X. XX disturbs XXXXXXXXX cell XXXX synthesis.
B XX inhibits XXX production XX viruses.
X. It XXXXXXXX XXXXXX XXX XXXXXXXXXXX.
D. It sends a messenger to the bone marrow XX produce XXXXX XXXXX XXXXX cells
121. XXXXXXXXX to your manual, how has the U.S. XXXXXXXXXX XXXXXXXXXXX changed in XXX XXXX XXX XXXXXXX?
A. Fewer and fewer XXXXXXXXXXXX drugs have been made available as OTCs.
B. Managed care XXX XXXX XXXXXXXXXXXX XXXXXXXX by XXXX XXXXXXX-XXXXXXXX approaches.
X. XXX XXXXX XXXX XXXXXX generation XXX XXXXX demanding XXXX XXXXXXXXXXXX attention.
D. XXXXX has XXXX XXXXXXXXX XXXXXXXX XX preventive health.
XXX. How XXXX XXXXXXXXXXXXXX marketing XXXX XXXXXX the XXXXXXXXX gap?
X. XX encourages XXXXXXXX XX take XXXX XXXXXX XXXXX in XXXXX healthcare.
X. XX XXXXX doctors XXXX XXXXXXXXX of XXX pharmaceutical XXXXXXXX.
X. XX makes XXXXXXXX XXXX XXXXXXXXX of XXXXX doctors' XXXXXXXX.
X. XXX XX XXXXX
123. XXXX do immunosuppressive agents do?
A. decrease risk of XXXXXXXXX
B. XXXXXXXX risk of XXXXXXXXX
C. reduce XXX XXXX XX rejection of foreign bodies
D. XXXXX psoriasis
124. XXXX types of XXXXX are EGFR inhibitors?
X. antineoplastics
X. XXXXXXXXXXXXXX XXXXXX
C. XXX XXXXXX
D. mitotic XXXXXXXXXX
125. XXXXX XX XXX XXXXXXXXX means outside XX the living body?
X. en vivo
B. ex vitro
X. ex XXXX
D. intra vivo
XXX. XXX XXX requirements for nutraceuticals and XXXXXXXXX XXXXX are XXXX XX XXXXXXXXX XX for XXXXXXXXXXXXXXX.
X. XXXX
B. XXXXX
XXX. What XX XXX XXXXXXXXX net XXXX XX XXXXXXX-sector healthcare's XXXXXXXXXXXXX to increased U.S. XXXX expectancy?
X. $5-XX XXXXXXX
B. $XX-50 XXXXXXX
C. $XXX-900 billion
X.$ X-5 XXXXXXXX
XXX. Which XXXXXXXXX XX TRUE XXXXXXXXX post-XXXXXXXX XXXX XXXXXXXXXX?
X. All XXXX effects are XXXXXXXXXX during XXXXXXXX trials.
X. XXXX XXXXXXXXXXXXX XXX only required to XXXXXX XXXXXXX effects XX XXXX are severe or life-threatening.
X. XXXX XXXXXXXXXXXXX are only required XX XXXXXX XXXXXXX XXXXXXX if they XXXX XXXX XXXXXX in clinical XXXXXXX.
D. XXX FDA XXX choose to XXXXXXXX XXXXX XXXXXXXX if new XXXXXXXX XXXXXX.
XXX. XXXXX term denotes when tolerance to XXX medication XXXXXX increased XXXXXXXXX XX XXXXXXX medication?
A. cell XXXXXXXXX
B. XXXXX-tolerance
X. XXXXXXXXX tolerance
D. minimized XXXXXXXXX
XXX. Patents XXXXXX __ XXXXX XXXX the date of XXXXXX.
X. XXX
B. XXXXXXX
X. twenty
X. thirty
XXX. After a XXXXX-name XXXX's patent expires, how may generic versions XX it be XXXX?
A. only under XXX XXXXXXX generic name
B. XXXX under the XXXXXXX XXXX
X. only under the XXXXXXXX XXXXX name
X. XXXXX the original trade name or a XXXXXXX XXXX
132. XXXX is XXXXXXXX XXX a new XXXXXXXXXXXXXX XX be XXXXXXXXXX a XXXXXX therapy?
X. XX causes XX XXXXXXX XXXXXXX XXXXXXX.
X. XX XXXXXX XX side XXXXXXX.
C. XX XXX an XXXXXX placebo.
X. XX is XXXX XXXXXXXXX XXX/or causes fewer serious XXXXXXX effects than other drugs on XXX XXXXXX.
XXX. XXXXX the AMA XXXXXXXXXX, XXX is ultimately XXXXXXXXXXX XXX minimizing XXXXXXXXX of interest?
X. doctors
B. XXXXXXX and office managers
X. pharmaceutical companies
D. sales XXXXXXXXXXXXXXX
134. XXX act XX XXXXXXXXXX a pharmaceutical alternative for XXX product prescribed is
X. alternative licensure
X. equivalence practice
X. necessitated XXXXXXXXXXXX
X. pharmaceutical XXXXXXXXXXXX
135. XXXX XXXX it XXXX XX a drug is said XX have a XXXX margin of XXXXXX?
X. Its XXXXXX levels have yet XX XX adequately verified.
B. Its safety varies widely XXXXX different XXXXX of XXXXXXXX.
C. There is a greater chance of severe or XXXX-XXXXXXXXXXX XXXX XXXXXXX.
X. There XX a lower XXXXXX XX severe or life-threatening side effects.
136. XXXXX of the XXXXXXXXX is XXX correct medical acronym for effective XXXX?
X. DE
X. ED
C. XXX
D. eff X
XXX. Why XX one XXXXX of XXXXXXXX XXXXX an active drug, XXXXX another XXXXX only receives a placebo?
A. to XXXXXX patients' expectations
X. XX assess the drug's effectiveness
X. XX XXXXXX XXX XXXXXXXXXXXXXXX of XXX study XXXXX
D. to XXXXXX XXX XXXXXXXX' demographics
138. A generic version XX likely to XXXX XXXX inactive XXXXXXXXXXX XXXX are different from XXXXX XX XXX original drug.
X. XXXX
X. XXXXX
139. XXXXX of XXX following XX an XXXXXXX of a functional value?
A. I XXXXX XXXX-XXXX XXXXXXX I am a citizen XX XXX world.
B. I drink XXXX-Cola XXXXXXX I like looking like a XXXXXXXXXXXXXX.
X. I drink XXXX-Cola because I XXXX the taste.
D. I drink XXXX-Cola XXXXXXX it is an international brand.
XXX. Where XXX XXXX drugs metabolized?
A. XXXXXXXXXXXX XXXXXX
B. liver
X. XXXXXXX
D . the bloodstream
XXX. What XX XXXXXXXXX XX XXX ethical XXXXXXXXXXX XXXX XXXXXXXX XX selected XXXXXX?
A. Selection criteria XXXXXX XX XXXX-XXXXXXXXX XX XXXXXXXXXX XXXXXXXX.
B. XXXXXXX should XXXX XXXXX XXXXXXX XX XXXXXXX XXXXXXXX on XXXXXXXX XXX XXX XXXXXXXXXXXXXXX XXX in XXXX XX medical attention.
C. XXXXXXXX XXXXXX XX XXXXXXXX based XX scientific objectives.
D. XXX XX XXXXX
142. XXXXX XX the following is the XXXX XXXXXXXXXXX salutation for a cover letter XX you cannot find a contact name?
X. XXXX Personnel XXXXXXXXXX.
X. Dear Sir or XXXXX,
X. Dear XXX
X.XX XXXX It XXX Concern.
XXX. XXXX XX part XX XXXXXXXX an indispensable XXXXXXXXXXXXXX sales XXX?
A. XXXXXX XXX feedback
B. XXXXXX XXX doctors XXXXXXXX they XXX for to XXXXXXXXX your XXXXXXXX
X. XXXXXXX XXXX XXXXXX share XXXXX the XXXX each XXXX
X. not bothering busy XXXXXXX in XXXXXXXXX
144. XXXXX of the XXXXXXXXX XX NOT typically included in XXX indications XXX usage section of the package insert information?
X. XXXXXXXX or XXXXXXXXXX XXXX the drug XX approved XX XXXXX
X. the drug's active metabolites
X. the XXXX's XXXXXXXXXXX XXXXX XXXXXX
D. the drug's XXXXX dosage range
XXX. XXXXX XXXX XXXXXXX XXX XXXXXXXX of classifying XXXXXXXXXX and XXXXX potential prescribers XX anticipated prescription XXXXXX?
X. conditioning
X. XXXXXXXX
C. XXXXXXXXX
X. private XXXXXXXX
XXX. XXXX XXXXX a XXXX eligible for fast XXXXX approval from the FDA?
A. It XX a XXXXXXX XXXX has already been XXXXXXXX as a XXXXXXX XXXX.
X. It XX a XXX drug.
C. XX XX XXXX expensive than what is currently XX XXX XXXXXX.
X. XX XXXXXX patients XXXX a serious. life-threatening condition.
147. In XXX XXXXXXXXXXXXXXXX tract, XXXX XXXXX up tablets XX ensure XXXX XXXXXXX XX XXX active pharmaceutical ingredient.
A. binders
X. disintegrants
X. XXXXXXXXXX agents
D. lubricants
148. According to XXXX manual, what XXXX XXX PDRP XX?
X. It educates XXXXXXXX on XXXXX XXXXXXXXX XXXXXXX.
B. It XXXXXXX XXXXX XXXXXXXXXXXXXXX' XXXXXX to XXXXXXX XXXXXXXXXXX.
X. It improves communication XXXXXXX XXXXX representatives XXX XXXXXXXX in XXXXXXX' XXXXXXX.
D. XX XXXXXX XXXXX XXXXXXXXXXXXXXX' abilities XX XXX XXXXXXXXXX XXXXXXXXXX' XXXXXXXXXXX XXXX.
XXX. XXXX XXX XXX components XX XXX central nervous XXXXXX?
X. XXX XXXXX XXX XXXXX organs
B. XXX brain and spinal cord
X. the XXXXX. XXXXXX cord. XXX peripheral nervous XXXXXX
X. XXX XXXXXX XXXX and sense organs
150. XXXXX term XXXXXXX XXX XXXXXX or cause of a XXXXXXX XXXXXXXXX?
A. XXXXXXXX
X. discovery
C. etiology
X. XXXXXXXXX
151. XXXXXXXX diagnosed with Type X diabetes...
A. ...do XXX produce XXXXXX insulin XXXXXXX XXXX XX XXX have XXXXXX X cells.
X. ...have an XXXXXXXXXX XXXXXXX.
C. ...XXXXXXX enough insulin. but it XX XXX XX XXXXXXXXX.
D. ...rely XX XXXXXXX from XXXXXXX XXXXXXX.
XXX. Which XXX XXXXXXXXXXXXXX marketing XXXXXX XX permitted in XXXXXXXX XXXXXXXXX?
A. XXXXXXX state XXX
X. branded billboards and XXXXXXX state XXX
C. XXXXXXX highway billboards
X. XXXXXXX radio XXX
XXX. XXXX XX one way in XXXXX XXXXXXXXXXXXX XXXXXX XXXX psychiatrists?
X. XXXXXXXXXXXXX are more XXXXXXXXX with XXXXXXXXXXXX XXXXXXXX than XXXXXXXXX XXXX.
B. Psychologists deal XXXX with XXXXXXXXX than XXXXXXXX issues.
X. Psychologists deal XXXX with XXXXXXXX XXXXXX than emotional ones.
X. XXXXXXXXXXXXX do not have XXXXXXXX XXXXXXX.
XXX. XXXX XXX PBMs?
A. XXXXXXXXXXXX organizations that provide healthcare
X. organizations that XXXXXX XXXXXXXXX XXXXXXXXX
X. XXXXXXXXXXXXX that negotiate between XXXXXXXXXXXXXX companies and XXXXX drug purchasers
X. organizations XXXX XXXXX XXX new drug applications
155. How does the Hatch-Waxman XXX XXXXXXX XXXXXXXX-XXXXX XXXX XXXXXXXXXXXXX?
X. by limiting XXX competition
X. by making it XXXXXX to XXXXX XXXXXXX drugs to market
C. by providing a 30-XXXXX XXXXXXX XXX period
D. XX requiring XXX FDA XX XXXX XXXX at bioavailability XXXXXXX XXXX XXXXXXXXX an ANDA
XXX. What XX the process of XXXXXXXXX drug doses to achieve XXX XXXXXXX positive XXXXXXXXXXX effects XXXXX XXXXXXXXXX adverse or XXXX XXXXXXX?
A. XXXXXXXXXXX maximization
X. steady stateadministration
X.XXXXXXXXX XXXXXXX
D. XXXXXXXXX
XXX. XXXXX XX the XXXXXXXXX is XXXXXXX XXXX in pharmacodynamics XXXX in pharmacokinetics?
A. XXXXXXXXXX. XXXXXXXXXXXX XXXXXXXXXX and XXXXXXXXX
B. XXXX-response effects
X. XXX XXXXXXXXXXXXXX of the XXXX to XXX specific site XXX drug-XXXXXXXX interaction
X. the way the XXXXX body deals XXXX a XXXX after it XXX XXXX XXXXXXXXXXXX
158. XXX does XXX XXXXXXX XXXXX immune system use XXX markers?
X. Substances XXXX MHC markers XXX XXXXXXXXX XX XXXXXXX XXX XXXXXXXX for destruction.
X. Substances XXXX MHC markers XX XXXXXXXXX XX foreign XXX quarantined in the XXXXX.
C. XXXXXXXXXX with XXX markers as discerned XX foreign and quarantined in XXX XXXXXXXX.
X. XXXXXXXXXX without MHC markers are XXXXXXXXX as XXXXXXX and XXXXXXXX for destruction.
XXX. XXXX is a behind-the-counter XXXX?
X. an XXX drug that must be XXXXXXX monitored by XXX XXXXXXXXXX
B. another XXXX XXX a generic XXXXXXXXXXXX XXXX
C. another XXXX for a XXXXXXXXXXXX XXXX
D. another XXXX for an XXX drug
XXX. When XX MSLs meet with clinicians?
X. XX XXXXXX XXX stage of XXX product's life cycle
X. XXXX XXXXX the district's sales representatives
C. XXXX prior XX launch
D. XXXX XX not XXXX XXXX physicians.
ANSWER
1. XXXXX XX XXX conditions XXXX XXXX XXX XXXX XX XXXXX. and then XX their mechanisms of XXXXXX
X. XXX a XXXX of stem cell XXXXXXX. XXXXXX patient's own cells XXX reinjected.
3. American Medical Association
4. XXXXXXXXXXXXXXXXX
X .highly XXXXXXXXXXX XXXXXXX XXX XXXXXXXX care provided by a large medical XXXXXX for unusual or complex XXXXXXX XXXXXXXX
6. XXXXX XXXXXXX
X. XXXXXXXX vascular resistance XXX increase XXXXX XXXX
X. XXXXXX XXXXX
X. Ocular XXXXXXXXXXXXXX XX XXXX primarily XX XXXXX the eye.
10. U.S. pharmaceutical XXXXXXXXX
11. via the kidneys
12. Limitations have XXXXXXXXX.
XX. XXXXXX: XXXXXXXX name
14. XXXX XXXXX are XXXXXXXXXXX in a neutral position.
15. Everyone XXXXX benefit XXXXXXX XXXX XXXXXXXXXX sampling XXXXXXXX
16. XX
XX . a physician who XXXXXXXXX internal medicine
18. XXXXXXXXXXX
19. XXXX are XXX. This XXX XX XXXXXXX reserved for more XXXXXXXXXXX reps.
20. XXXXXXXXXXXXXXXX studies how drugs affect the body.
21. about 70%
XX. directly XXXX XXXXX XXXXXXXXXXXXXXX
23. I buy Advil XX show that I'm a XXXXXX XXXXXXXX.
XX. XXXXXXXXXX
XX. XXX availability of XXXXXXXX and energy
XX. It has been shortened XX XXXXXX the XXXX of new XXXX development.
27. XXXXXXXXXXX XXXXXXXXXXXXX how generics XXXXXX from brand XXXX drugs
XX. the XXX
29. totipotent
XX. XX XXXXXXX XXXXXXXXXX XXXXXXX the XXXXXXXXXXXX is XXXXXX.
XX. XXXXXXX and XXXXXX
XX. the XXXXXXXX system
XX. by XXXXXXX to cell XXXXXXXXX that XXX XXXXXXXXX XX XXXXX XXXXXXXX
34. Orange Book
35. beneath the outer skin
36. XXX staff XXX permission XX move XXXX XX XXX other XXXXXXXX in the XXXXXXX
XX. TRUE
XX. XXXXXXXXXXXXXX
XX. primary and XXXXXXXXX XXXXXXXXX distributors
XX.C or X. off-XXXXX
XX. XX
XX. TRUE
43. Pharmaceutical XXXXX reps are XXX concerned XXXXX XXXXXXXXXXX.
XX. XXX X.S. Patent and Trademark XXXXXX
XX. XXXXXXXXXXX
XX. Potency XXXXXX to XXX drug's XXXXXXXX, XXXXX efficacy XXXXXX XX XXX XXXXXXXXXXXXX.
XX. a graduate degree
XX. XX least XXXXX
XX. Answer: Increasing the XXXX of XXXXXXX
XXXXXXXXXXXX (XXXXXX Not XXXXX so XXXX out in below para): Lengthening XXXXXXXXXXX XXXX XXXXXXXXXXXX XXXXXXXX XXX cost of bringing a XXX XXXX XX market XX XXXXXXXXXX the XXXX of capital XXXXXX for R&XXX;X. The XXXX XX capital XXXXXXXXX XX companies are exposed XX Economic Risk XXX uncertainty over a XXXXXX period XX development time. Stringent XXX guideline XXX XXXX approval times XXXX greatly increased XXX cost XX developing new drugs.
50. XXXXX
XX. XXX
52. XXXX a XXXXXXXXX XXXXXX moves through a XXXXXXXX from a XXXX XXXXXXXXXXXXX XXXXXXXX to a XXX one
53. XXXXXXXXXXXX and XXX XXXXXXXXXXXX
54. XXXXXX: XXXXXXXX
55. XXXXXXXX XX metabolism
56. XXXXX
57. edema
58. be a XXXXXXXXXX. not a rep
59. XXXXXXXX
60. XXXXXXXXXXXX
61. XXXXXXXXX
62. adjuvant
63. XX probably has XXXXXXXXX XXXXXXXXX status if it is not XX parity XXXX XXX other XXXXX.
64. homeostasis
XX. Agonists and antagonists XXX XX XXXX XXXXXXXX.
XX. XXXXXXXX pharmacology
XX. XXXX XXXX sample XXXXXX XX XXX XXXXXXXXXXXXX
68. GPO
XX. large XXXXXXXX
70. XXXX sampling XX often forbidden.
71. XXXXXX if he or she is having any XXXXXXXX with the managed care coverage XX your products
72. margin of XXXXXX
XX. XXX inert XXXXXXXXXXX in a drug XXXXXXXXXXX
XX. XXXX XXXXX
XX. XX induce XXXXX
XX. none of these
XX. XX pass through the XXXXXXX more quickly
78. XXXXXXXXX XXXXXX center formularies are XXXX XXXXXXXXXXX.
XX. Doctors XXXXX use XXXX XXXXXXX XX XXXXX patients XXX XXXXXXXXX XXXXX not XXXXXX it.
80. XXXXXXXXXXXX
81. prevent dissolution in the XXXXXXX
XX. 7 years
XX. XXXXXXXXX contracts XXXX MCOs XXX XXXX
84. XXX manufacturer XXX recalled XXX product XX XXX own. but XXXXXXXXXX with XXX FDA beforehand.
85. XXXXX XXX
86. Phase II
XX. XX XXXXXXX XXXXXXX pH
88. XXXXXX time
89. equal XXXXXXX of XXXXXXXXX XXXXX the XXXXXXXX in both directions
90. XXXXXXX
XX. upcharge
92. Chronic XXXXXXXXX persist for a long time. whereas delayed XXXXXXXXX XXXX some time to develop.
XX . XXX response XXXXXXXX by a XXXXXXXXXX
XX. a patient forgetting XX XXXX a XXXX at a XXXXXXXXX XXXX XX day
XX. XXXXX a XXXXXX
96. Representatives do XXX XXXX to the end user XX XXX XXXXXXX.
97. XXXXXXXXXXXXX
XX. an XXX of XXX XXXXXXXXXX XX XXXXXX and Human XXXXXXXX
XX. the XXXXXXXX of XXX XXXXXXXX XXXXX XXXXXXX XXX the XXXXXX it XXX XX the XXXXXXX's quality XX life
XXX. the United States XXXXXXX XXXX Council
101. XXXX of these
XXX. XXX drug must XX XXXXX-soluble. XXX XXX bind XXX tightly to proteins in the XXXXXXXXXXX.
XXX. XXXXXXX
104. chemical
XXX. unacceptable
XXX. legislation
XXX. XXXXXXXX
108. XXXX XX XXXXXXXXX XXXXXXXX
109. XXXXXXXX
XXX. safety
XXX. never
XXX. XXXXX II XXXXXX
113. XXXXXXXXXXX vaccines have a more XXXXXX shelf life.
XXX. XXXXXXXX
115. (1) professional XXXXXXXXX XXXXXXXXXX. XXX (2) direct-XX-consumer advertising
116. fatty tissuebeneath the surface of XXX skin
XXX. the proprietary name XXX the XXXXXXXXXXX XXXX
XXX. pharmacokinetics
119. likeability factor
120. XX XXXXXXXX XXXXXXXXX cell XXXX XXXXXXXXX.
121. XXXXXXX care has XXXX XXXXXXXXXXXX XXXXXXXX XX XXXX patient-centered approaches.
XXX. It encourages XXXXXXXX XX XXXX more XXXXXX XXXXX in XXXXX healthcare.
XXX. XXXXXX the risk XX rejection of XXXXXXX XXXXXX
XXX. XXXXXXXXXXXXXXX
125. ex XXXX
126. FALSE
XXX. $ X-5 trillion
XXX. XXX XXX XXX choose to XXXXXXXX their XXXXXXXX if XXX XXXXXXXX XXXXXX.
XXX. cross-XXXXXXXXX
130. twenty
131. XXXX under the branded generic name
XXX. XX is more effective and/or XXXXXX XXXXX serious adverse XXXXXXX XXXX XXXXX XXXXX on XXX XXXXXX.
XXX. XXXXXXX
XXX. XXXXXXXXXXXXXX substitution
135. XXXXX is a XXXXX XXXXXX of XXXXXX or life-threatening XXXX effects.
136. XX
XXX. XX assess XXX drug's effectiveness
XXX. XXXX
XXX. I XXXXX XXXX-Cola XXXXXXX I like the XXXXX.
140. liver
141. Subjects should XX selected XXXXX on XXXXXXXXXX objectives.
142. XXXX Sir or XXXXX,
XXX. XXXXXX for feedback
XXX. XXX XXXX's active XXXXXXXXXXX
145. XXXXXXXX
146. XX XXXXXX XXXXXXXX with a XXXXXXX. XXXX-threatening condition.
147. disintegrants
XXX. XX limits XXXXX representatives' XXXXXXXXX XX XXX XXXXXXXXXX physicians' prescribing XXXX.
149. XXX XXXXX XXX spinal cord
150. etiology
151. XXXX an autoimmune disease.
152. disease XXXXX XXX
153. XXXXXXXXXXXXX XXXX more with XXXXXXXXX than physical issues.
154. organizations that XXXXXXXXX between XXXXXXXXXXXXXX companies and XXXXX drug purchasers
XXX. XX XXXXXXXXX a XX-month XXXXXXX XXX XXXXXX
XXX. XXXXXXXXX
XXX. XXX transportation XX XXX XXXX to XXX XXXXXXXX XXXX for XXXX-receptor interaction
XXX. XXXXXXXXXX without MHC XXXXXXX are discerned as foreign and targeted for destruction.
159. an XXX drug that XXXX be XXXXXXX monitored XX XXX XXXXXXXXXX
160. at nearly XXX stage of the product's XXXX cycle
">